Title :

Patient-reported outcomes in keynote-087, a phase 2 study of pembrolizumab in patients with classical hodgkin lymphoma

Author(s) :

von Tresckow, Bastian [Auteur]
Fanale, Michelle [Auteur]
Ardeshna, Kirit M. [Auteur]
Chen, Robert [Auteur]
Meissner, Julia [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Moskowitz, Craig [Auteur]
Zinzani, Pier Luigi [Auteur]
Giezek, Hilde [Auteur]
Balakumaran, Arun [Auteur]
Vo, Thao T. [Auteur]
Raut, Monika [Auteur]
Brice, Pauline [Auteur]

Journal title :

Leukemia & lymphoma

Abbreviated title :

Leuk. Lymphoma

Pages :

1-7

Publication date :

2019-04-23

ISSN :

1029-2403

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. ...
Show more >In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (nnnShow less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Research team(s) :

Modélisation biopharmaceutique et pharmacocinétique

Submission date :

2019-12-16T14:06:40Z